Studies have revealed that the upregulation of immune checkpoints such as PD-1, LAG-3, and B7-H3 in glioma aids tumor immune evasion, resulting in T cell dysfunction (81–86), which suggests that NR2F6 may promote glioma immune evasion through upregulation of immune checkpoint expression. This evidence concerns the gene CD276 and neoplasm.